Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) — Medicare Part D spending
Eli Lilly & Co. · Rank #339 by total Part D spend · CMS data year 2023
Medicare Part D spent $124,346,168 on Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) in 2023, the #339 drug by total Part D spending out of 3,598 drugs. That worked out to about $25.46 per dosage unit, $812 per claim and $3,429 per beneficiary, across 153,133 claims for 36,266 beneficiaries. Average spending per dosage unit rose +0.4% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Note: CMS flagged this drug as a spending-per-dosage-unit outlier for 2023 (a large reported change that may reflect new dosage forms, reformulation or low volume). Read the per-dosage-unit figure with care.
Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) spending at a glance (2023)
| Metric | Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) |
|---|---|
| Total Part D spending (2023) | $124,346,168 |
| Total spending (2022) | $116,027,391 |
| Year-over-year change in total spending | +7.2% |
| Average spending per dosage unit (2023) | $25.46 |
| Change in spend per dosage unit (YoY) | +0.4% |
| Avg annual change per dosage unit (2019-2023 CAGR) | -0.6% |
| Average spending per claim (2023) | $812 |
| Average spending per beneficiary (2023) | $3,429 |
| Total claims (2023) | 153,133 |
| Beneficiaries (2023) | 36,266 |
| Total dosage units (2023) | 4,883,385 |
| Manufacturer(s) | Eli Lilly & Co. |
| National rank by total spend (of 3,598 drugs) | #339 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $116,027,391 | $124,346,168 | +7.2% |
| Avg spend per dosage unit | $25.37 | $25.46 | +0.4% |
| Avg spend per claim | $806 | $812 | — |
| Avg spend per beneficiary | $3,458 | $3,429 | — |
| Total claims | 143,893 | 153,133 | — |
| Beneficiaries | 33,550 | 36,266 | — |
How Humulin 70/30 Kwikpen compares with nearby drugs
Drugs with total Part D spending closest to Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) (this drug, #339) | $124,346,168 | $25.46 | +0.4% |
| Skyrizi On-Body (Risankizumab-Rzaa) (#337) | $125,306,777 | $9,002.43 | +13.5% |
| Carbidopa-Levodopa (Carbidopa/Levodopa) (#338) | $125,111,276 | $0.20 | -5.1% |
| Iclusig (Ponatinib HCl) (#340) | $123,338,680 | $686.96 | +6.1% |
| Valacyclovir (Valacyclovir HCl) (#341) | $121,564,610 | $1.04 | -12.4% |
| Divalproex Sodium ER (Divalproex Sodium) (#342) | $120,375,972 | $0.93 | -19.4% |
Frequently asked questions
How much does Medicare Part D spend on Humulin 70/30 Kwikpen?
Medicare Part D spent $124,346,168 on Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) in 2023 (the latest CMS data year), across 153,133 claims for 36,266 beneficiaries. That ranks #339 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Humulin 70/30 Kwikpen?
In 2023, the weighted average Medicare Part D spending per dosage unit for Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) was $25.46. Compared with 2022 it rose +0.4%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Humulin 70/30 Kwikpen?
CMS attributes Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) to Eli Lilly & Co. in the 2023 Part D spending file. Average spending per claim was $812 and per beneficiary $3,429.
Is the Humulin 70/30 Kwikpen figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20